Leflunomide-induced Toxic Epidermal Necrolysis in a Patient with Rheumatoid Arthritis
Journal of Rheumatic Diseases
;
: 326-330, 2014.
Article
Dans Anglais
| WPRIM
| ID: wpr-54157
ABSTRACT
Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998 and has been available in Korea since 2003. Allergic cutaneous reactions (rash, purpura) are common (<10%) side effects of leflunomide, but severe cases such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) are rarely reported. There has not been a report of SJS or TEN induced by leflunomide in Korea. Here we report a case of leflunomide-induced TEN in a patient with rheumatoid arthritis. Leflunomide was discontinued, and the TEN was treated with methylprednisolone, cholestyramine and immunoglobulin. The skin lesion eventually resolved over four weeks with residual post-inflammatory hyperpigmentation.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Polyarthrite rhumatoïde
/
Peau
/
Immunoglobulines
/
Méthylprednisolone
/
Résine de cholestyramine
/
Syndrome de Stevens-Johnson
/
Hyperpigmentation
/
Corée
Limites du sujet:
Humains
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
Journal of Rheumatic Diseases
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS